UiPath assumed with an Equal Weight at Morgan Stanley

Morgan Stanley assumed coverage of UiPath with an Equal Weight rating and $15 price target. UiPath “cleared a lowered bar with a solid beat and raise” in Q2, notes the analyst, who adds that the Q2 results showed signs of better execution after “a disappointing start to FY25.” The ongoing challenge is that net-new ARR is still declining materially and high end of FY25 ARR guidance suggests that this will continue, adds the analyst, who thinks the debate on the shares will “remain unresolved for the foreseeable future.”